Introduction {#s1}
============

IBMPFD is an autosomal dominant disease that afflicts multiple body systems ([@bib28]). 90% of IBMPFD patients display skeletal muscle weakness (myopathy), the primary and earliest symptom of IBMPFD ([@bib62]). With progression of the disease, 50% of patients will develop Paget's disease of bone, affecting the skull, spine, hips and long bones of all four limbs. One-third of the patients will also develop frontotemporal dementia ([@bib62]; [@bib29]). Single missense mutations of *p97/cdc48/Valosin-containing protein (VCP)* cause fully penetrant IBMPFD ([@bib60]). *VCP* mutations are also associated with 1--2% of cases of amyotrophic lateral sclerosis (ALS), familial hereditary spastic paraplegia (HSP) and Charcot-Marie-Tooth 2 (CMT2) disease ([@bib1]; [@bib15]; [@bib22]).

*VCP* encodes a highly conserved and abundant AAA+ ATPase which participates in multiple cellular processes ([@bib34]). Human p97/VCP and its *Drosophila* homologue have 85% identity and 93% similarity in protein sequence. VCP has three major domains: the regulatory N domain, and the D1 and D2 ATPase domains. VCP hexameric rings utilize the energy from ATP hydrolysis to promote protein and RNA homeostasis, often by directly or indirectly modifying the fate of ubiquitin-labeled proteins ([@bib34]). VCP functions in multiple contexts that include protein quality control in the endoplasmic reticulum ([@bib67]; [@bib54]), chromatin modification ([@bib46]; [@bib19]; [@bib58]), endolysosomal sorting ([@bib49]), membrane fusion ([@bib71]), autophagosome/lyosome function ([@bib25]; [@bib24]), ER protein translocation ([@bib16]; [@bib61]), formation of stress granules ([@bib5]) and ciliogenesis ([@bib47]). VCP interacts with a number of co-factors to regulate these processes ([@bib35]; [@bib34]), making it challenging to identify the molecular basis of phenotypes associated with disease mutations.

Disease-causing, single missense mutations of VCP are mainly located in the N-terminal half of the protein, either in the N domain or the D1 domain. Among them, the R155H mutation is the most frequently identified in IBMPFD patients, while the A232E mutation is associated with the most severe clinical manifestation ([@bib28]; [@bib48]). *In vitro* assays show that disease mutants have enhanced ATPase activity ([@bib61]; [@bib70]; [@bib40]; [@bib33]; [@bib55]). However, because VCP assembles as a hexamer, it is controversial whether disease mutants with increased ATPase activity cause disease through a dominant-active ([@bib7]) or dominant-negative mechanism ([@bib49]; [@bib25]; [@bib27]; [@bib3]; [@bib30]).

VCP disease mutants predominantly affect organs that have a high level of energy expenditure, such as brain and muscle. Mitochondria provide the bulk of the ATP to these tissues through oxidative phosphorylation, and mitochondrial functional defects, including mitochondrial uncoupling and decreased ATP production, are observed in IBMPFD patient fibroblasts ([@bib3]; [@bib37]). Abnormal mitochondria are also observed in transgenic VCP disease mutant R155H mice as well as VCP R155H knock-in mice ([@bib13]; [@bib38]). These observations suggest that mitochondrial dysfunction is important for the pathogenesis of IBMPFD, but the mechanism by which VCP mutation alters mitochondrial function is not clear.

Mitochondrial morphology is controlled by dynamic cycles of fusion, controlled by Mitofusin (Mfn), and fission, regulated by DRP1 ([@bib6]). Recent studies have uncovered the roles of mitochondria fusion and fission defects in the pathogenesis of multiple neurodegenerative disorders ([@bib14]; [@bib10]; [@bib59]), particularly Parkinson\'s disease, the second most common neurodegenerative disorder ([@bib23]; [@bib43]; [@bib17]; [@bib66]; [@bib44], [@bib45]; [@bib41]). In mammals, homologous proteins Mitofusin 1 and 2 (Mfn1 and Mfn2) mediate mitochondrial outer membrane fusion, with loss of function of Mfn 1 and 2 resulting in fragmented mitochondria and multiple defects in mitochondrial function ([@bib10]). In Hela cells, VCP promotes Mfn 1 degradation ([@bib64]). VCP also mediates Mfn 1 and 2 degradation when mitophagy is stimulated in mammalian cells, and overexpression of VCP in *Drosophila* leads to downregulation of a tagged Mfn-transgene ([@bib27]; [@bib30]). These observations led us to investigate the mitochondrial basis and molecular mechanisms for VCP disease mutants function using both *Drosophila* and IBMPFD patient cell models. As IBMPFD show the highest penetrance in muscle, with 90% of patients manifesting phenotypes in this tissue, we generated *Drosophila* models of IBMPFD in muscle, which recapitulate disease pathologies. We provide evidence in both *Drosophila* and human patient cells that VCP disease mutants have an enhanced ability to promote Mfn degradation, loss of which is associated with defects in mitochondrial fusion and physiology. Consistent with the hypothesis that VCP disease phenotypes are due to increased activity on substrates, we find that VCP ATPase activity inhibitors such as NMS-873 and ML240 can significantly rescue mitochondrial defects, disrupted muscle integrity and muscle cell death *in vivo* in *Drosophila*, and mitochondrial fusion and respiration defects in IBMPFD patient fibroblasts.

Results {#s2}
=======

Endogenous VCP regulates mitochondrial fusion via negative regulation of Mfn protein levels {#s2-1}
-------------------------------------------------------------------------------------------

Since VCP disease mutants have dramatic muscle phenotypes in humans and mouse models, and these are associated with defects in mitochondrial structure and function, we first examined the consequences of manipulating VCP levels. The *Drosophila* adult indirect flight muscle (IFM) is a non-essential, post-mitotic, and energy-intense tissue containing a high density of mitochondria. It also shows strong and consistent phenotypes in response to altered expression of genes required for mitochondrial fusion, fission and quality control ([@bib12]; [@bib17]; [@bib66]; [@bib44]; [@bib41]; [@bib45]; [@bib69]). Using the UAS-Gal4 system ([@bib4]), we expressed VCP under the control of an IFM promoter derived from the *flightin* gene we previously generated ([@bib69]). While expression of VCP under the control of the pan-muscle Gal4 drivers 24B-Gal4 or Mef2-Gal4 resulted in 100% adult lethality, expression of wildtype VCP under IFM control, which provides a pulse of expression in late pupal stages and early adulthood, gave rise to viable flies with intact and healthy muscle following adult eclosion. We utilized mitochondrially targeted GFP (mitoGFP) as a mitochondrial marker, as well as transmission electron microscopy (EM) at the ultrastructual levels for enhanced resolution particularly for cristae morphology. In 2-day-old flies, expression of VCP results in muscle with small mitochondria with intact cristae ([Figure 1---figure supplement 1A--B'](#fig1s1){ref-type="fig"}). Similar phenotypes are also observed in muscle from 6-day-old VCP-expressing flies ([Figure 1A--B''](#fig1){ref-type="fig"}). Conversely, expression of UAS-VCP RNAi under IFM control (VCP RNAi flies) results in mitochondria with an elongated phenotype ([Figure 1C--C''](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C and C'](#fig1s1){ref-type="fig"}). Two independent VCP RNAi lines were utilized and both showed significant knockdown ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).10.7554/eLife.17834.003Figure 1.Endogenous VCP regulates mitochondrial fusion via negative regulation of Mfn protein levels.(**A--C**) MitoGFP localization to mitochondria serves as a marker for healthy mitochondria and their morphology in the indirect flight muscle. VCP overexpression (VCP OE, **B**) results in small mitochondria compared to wildtype (WT) flies (**A**); VCP RNAi expression results in elongated mitochondria (**C**). Scale Bar: 5 µm. (**A'--C''**) Electronic microscopic (EM) images show that VCP OE (**B'--B''**) results in smaller mitochondria as compared with WT (**A'--A''**). VCP RNAi generates elongated mitochondria with intact cristae (outlined with white dashed lines in **C'** and **C''**). (**A'--C'**) Lower magnification; (**A''--C''**) Higher magnification of mitochondria outlined with black solid lines in **A'--C'**. Scale bar: 1 µm. (**D**): Schematic diagram of nurse cell mosaic analysis in *Drosophila* female germline. A stage 10A egg chamber has three types of cells. The monolayer follicle cells coat the surface of the egg chamber; 15 nurse cells provide proteins and RNAs to the oocyte during oogenesis. Heat shock induction of mitotic recombination during larvae stages results in the creation of a mosaic pattern in the adult nurse cells. Ubi-mRFP.NLS (Red) is used as a clone marker. Wildtype (WT) cells are labeled with two copies of RFP, +/+; heterozygous mutant cells have one copy of RFP and one copy of *vcp* loss-of-function mutant, *vcp^K15502^/+*; homozygous mutant cells are RFP negative and have two copies of *vcp* loss-of-function mutant, *vcp^K15502^/vcp^K15502^*. (**E**): A stage 10A egg chamber with a mosaic pattern of nurse cells. Red signal is Ubi-mRFP.NLS. Scale bar: 20 µm. (**E'**) Anti-ATP5A antibody staining is used to visualize mitochondrial morphology in nurse cells. Scale bar: 20 µm. (**F--I**) Higher magnification view of mitochondrial morphology in E' (outlined in white solid lines). Mitochondria appear as discrete and punctate structures in wildtype (**G**) and heterozygous *vcp* mutant cells (**F**), but becomes elongated and clumped in homozygous *vcp* loss-of-function mutant cells (**H and I**). Scale bar: 5 µm. (**J**) A stage 10B egg chamber with a mosaic pattern of nurse cells. Red signal is Ubi-mRFP.NLS; Green signal is anti-GFP staining of pCasper-Mfn-eGFP. Scale bar: 20 µm. (**J'--J''**) Higher magnification of the egg chamber in J (outlined in white solid lines). Wildtype cells are RFP positive and homozygous *vcp* loss-of-function mutant cells are RFP negative (**J'**). pCasper-Mfn-eGFP levels significantly increase in homozygous *vcp* loss-of-function mutant cells (**J''**). Scale bar: 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.003](10.7554/eLife.17834.003)10.7554/eLife.17834.004Figure 1---figure supplement 1.VCP overexpression leads to smaller mitochondria, while VCP RNAi leads to elongated mitochondria in 2-day-old indirect flight muscles.(**A--C'**) EM shows that compared to WT (IFM-Gal4 control, **A** and **A'**), VCP WT has smaller mitochondria with intact cristae (**B** and **B'**). VCP RNAi results in mitochondrial elongation (**C** and **C'**) in 2-day-old flies. Scale bar: 1 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.004](10.7554/eLife.17834.004)10.7554/eLife.17834.005Figure 1---figure supplement 2.IFM-Gal4 driven UAS-VCP RNAi results in a significant decrease in VCP levels.Expression of VCP RNAi line 1 and RNAi line 2 result in a decrease in VCP levels to 45.06 ± 11.17% (p=0.014) and 42.29 ± 1.12% (p=0.037) of those present in WT. Independent t test is used for statistical analysis, N = 3. Normalized VCP levels are shown as mean±½SD.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.005](10.7554/eLife.17834.005)10.7554/eLife.17834.006Figure 1---figure supplement 3.pCasper-Mfn-eGFP colocalizes with the mitochondria marker ATP5A, and is silenced by expression of dsRNA targeting endogenous Mfn.(**A**) One nurse cell of a stage 10B egg chamber in transgenetic flies carrying the genomic rescue of Mfn (pCasper-Mfn-eGFP). The pCasper-Mfn-eGFP construct expresses Mfn-eGFP under the control of the endogenous Mfn promoter. GFP signal colocalizes with anti-ATP5A staining, indicating mitochondrial localization. Scale bar: 20 µm. (**B**) S2 cells were transfected with pCasper-Mfn-eGFP and blotted and probed with anti-GFP antibody. Mfn dsRNA treatment results in loss of Mfn-eGFP expression.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.006](10.7554/eLife.17834.006)

To explore the generality of VCP's ability to regulate mitochondrial morphology we also examined mitochondrial morphology phenotypes of a *vcp* loss-of-function mutation. *vcp* null mutants in *Drosophila* are embryonic lethal ([@bib50]). The indirect flight muscle is a cellular syncytium and therefore cannot be used for mosaic analysis. As an alternative, we focused on the *Drosophila* female germline, in which a *vcp* loss-of-function mutant can be monitored in individual nurse cells, which are relatively large and offer great resolution for examining mitochondrial morphology. *vcp^K15502^* is a strong loss-of-function allele that has a P element insertion at the 5'-UTR of *Drosophila VCP* gene ([@bib7]; [@bib50]) and has been used to generate *vcp* loss-of-function clones in imaginal discs ([@bib72]). The *Drosophila* ovary consists of numerous developing egg chambers. Each egg chamber develops from stage 1 to stage 14 and has three types of cells: follicle cells, nurse cells and the oocyte ([@bib20]). The germline complement of each egg chamber (15 nurse cells and the oocyte) derives from four sequential divisions of a single daughter of a stem cell. We utilized the FLP/FRT system ([@bib56]) to create mitotic recombinants in which nurse cells were either wildtype (+/+), heterozygous (*vcp^K15502^/+*) or homozygous (*vcp^K15502^/vcp^K15502^*) for the *vcp* loss-of-function mutation ([Figure 1D](#fig1){ref-type="fig"}). In this system wildtype and heterozygous *vcp* loss-of-function mutant cells carry 2 or 1 copies of ubi-mRFP.NLS (RFP) respectively, whereas the homozygous *vcp* mutant cells are RFP negative ([Figure 1E](#fig1){ref-type="fig"}). Anti-ATP5A antibody is used to visualize mitochondrial morphology in nurse cells ([Figure 1E'](#fig1){ref-type="fig"}). Mitochondria in wildtype and heterozygous *vcp* mutant cells have a punctate morphology ([Figure 1F and G](#fig1){ref-type="fig"}). In contrast, in homozygous *vcp* loss-of-function mutants mitochondria are more tubular and clumped ([Figure 1H and I](#fig1){ref-type="fig"}). Together, these results suggest that endogenous VCP negatively regulates mitochondrial fusion or positively regulates fission.

Next, we investigated how *vcp* loss-of-function leads to elongated mitochondria. First, we examined the expression levels of Mfn in the female germline, using mosaic analysis, as above. We used a tagged genomic rescue transgene (pCasper-Mfn-eGFP, a transgene construct with a GFP tagged Mfn under the control of its endogenous promoter, a kind gift from Dr. CK Yao) to monitor the endogenous Mfn level as the existing anti-Mfn antibody lacked sufficient sensitivity. As expected, the genomic rescue Mfn-eGFP signal colocalizes with the mitochondria marker ATP5A in the nurse cells ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). This signal is eliminated following Mfn RNAi, indicating that genomic rescue Mfn-eGFP is a reliable marker for endogenous Mfn ([Figure 1---figure supplement 3B](#fig1s3){ref-type="fig"}). In each egg chamber, *vcp* loss-of-function cells are adjacent to wildtype cells, providing an ideal opportunity to unambigously compare the levels of Mfn. As shown in [Figure 1J--J''](#fig1){ref-type="fig"}, nurse cells homozygous for a *vcp* loss-of-function mutant have greatly increased Mfn levels compared to wildtype and heterozygous *vcp* loss-of-function cells. The findings that endogenous VCP regulates Mfn *in vivo* are unexpected and important, as VCP is a highly abundant cytosolic protein with many targets and VCP does not show appreciable localization to mitochondria in unstressed cells.

Second, we examined whether alteration of *vcp* can regulate Mfn levels in tissue lysate. Overexpression of wildtype VCP (VCP OE) in the flight muscle resulted in a decrease in endogenous Mfn levels ([Figure 2A](#fig2){ref-type="fig"}). VCP overexpression also caused a decrease in the levels of Mfn when Mfn was overexpressed (Mfn OE) using the IFM promoter, suggesting that VCP regulates Mfn post transcriptionally ([Figure 2A](#fig2){ref-type="fig"}). Conversely, VCP RNAi resulted in an increase in endogenous Mfn levels in a wildtype background, and an increase in total Mfn levels in the presence of Mfn OE ([Figure 2B](#fig2){ref-type="fig"}). In contrast, VCP overexpression does not alter the levels of pro-fission protein DRP1 ([Figure 2C](#fig2){ref-type="fig"}). In addition, VCP's regulation of Mfn is specific and not part of a general mitophagy response since the levels of other mitochondrial proteins, such as the outer membrane protein Porin, the inner membrane protein NDUSF3, and the matrix protein MnSOD, are not altered ([Figure 2D](#fig2){ref-type="fig"}).

VCP physically interacts with Mfn via the N and D1 domains {#s2-2}
----------------------------------------------------------

To explore the possibility that Mfn is a direct target for VCP, we asked if Mfn could physically interact with VCP in immunoprecipitation assays from S2 cells. Indeed, full length VCP strongly interacts with Mfn ([Figure 2E](#fig2){ref-type="fig"}). This is consistent with previous findings ([@bib27]). VCP has been shown to interact with substrate through the D1 ATPase domain, with the presence of the N domain being essential for the interaction ([@bib34]). As shown in [Figure 2E](#fig2){ref-type="fig"} , this is also the case with the VCP-Mfn interaction. When the N domain of VCP is deleted, the strength of VCP-Mfn interaction is decreased, and it is undetectable when N and D1 are both deleted. In contrast, removal of the D2 domain has no effect on interaction between VCP and Mfn. Interestingly, Mfn levels in the input blot are decreased under conditions when VCP and Mfn interact, but not under conditions in which interactions are not observed, consistent with the hypothesis that direct interaction between VCP and Mfn is required for Mfn degradation. Together, these observations suggest that Mfn is a specific, direct target of VCP.10.7554/eLife.17834.007Figure 2.Mfn is a specific target of VCP.(**A**) In fly thoraxes, VCP OE in wildtype (IFM-Gal4 control) and Mfn OE background results in a significant decrease in Mfn levels. Hsp60 was used as a mitochondria control; Actin was used as a loading control. (**B**) VCP RNAi leads to enhanced Mfn levels (1.72 ± 0.37 compared to wildtype, set as 1; p=0.021, independent t-test, N = 4). VCP RNAi results in accumulation of Mfn in the Mfn OE background (16.15 ± 0.85 as compared to Mfn OE alone, 9.02 ± 1.63, wildtype set as 1, p=0.0101, independent t test, N = 3). \*p\<0.05. Mfn levels are normalized with Hsp60 and are displayed as mean±½SD. (**C**) VCP OE also does not result in changes in the levels of the pro-fission protein DRP1 level (p=0.088, independent t test, N = 3). DRP1 was detected using an HA tagged genomic rescue transgene expressed under the control of the endogenous DRP1 promoter (pCasper-DRP1-HA). n.s.: no statistical difference. (**D**) Markers for various mitochondrial compartments, including Porin (outer membrane), MnSOD (matrix), and NDUSF3 (inner membrane) were not altered by VCP overexpression. (**E**) Schematic diagram of full length and truncated VCP forms used in protein interaction assays in S2 cells. Protein interactions are assayed between full length and truncated VCP forms and Mfn. N and D1 domains are essential domains for the VCP-Mfn interaction.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.007](10.7554/eLife.17834.007)

VCP suppresses *PINK1/parkin* mutant mitochondrial phenotypes in muscle {#s2-3}
-----------------------------------------------------------------------

Mutations in *PINK1* and *Parkin* lead to autosomal recessive forms of Parkinson's disease (PD) ([@bib31]; [@bib57]). We and others have shown that *PINK1* and *Parkin* function in the same pathway, with *PINK1* positively regulating *Parkin* to control mitochondrial integrity and quality control in *Drosophila* ([@bib12]; [@bib65]; [@bib42]). Importantly, levels of Mfn are significantly increased in *PINK1* and *parkin* null mutants and downregulation of Mfn protein levels suppresses phenotypes in both mutants ([@bib17]; [@bib66]; [@bib41]; [@bib68]). The results presented above suggest that expression of VCP, by decreasing the level of Mfn, could also suppress *PINK1/parkin* phenotypes. Kim et al. have argued that VCP expression suppresses *PINK1*, but not *parkin* loss-of-function phenotypes. This, along with their observation that VCP levels at mitochondria increased following expression of Parkin in the presence of CCCP, suggested a model in which VCP action on mitochondria requires recruitment by Parkin ([@bib27]). Because the EDTP-Gal4 driver used in these earlier experiments does not express at significant levels in flight muscle ([@bib53]) ([Figure 3J](#fig3){ref-type="fig"}, see GFP signals), we reexamined this issue. We expressed VCP in the flight muscle of *PINK1* and *parkin* mutants. As previously shown ([@bib65]; [@bib12]; [@bib42]), *PINK1* and *parkin* null mutants show mitochondrial defects and tissue disintegration with vacuolation in muscle ([Figure 3A--B'' and D--D''](#fig3){ref-type="fig"}). At the ultrastructural level, *PINK1* and *parkin* mutants display swollen mitochondria with a broken cristae ([Figure 3A''', B''' and D'''](#fig3){ref-type="fig"}). VCP OE completely suppressed tissue damage and mitochondrial defects ([Figure 3C--C''' and E--E'''](#fig3){ref-type="fig"}). The thorax indentation phenotype in *PINK1/parkin* mutants is also completely suppressed by VCP overexpression under the control of the IFM-Gal4 driver, but not the EDTP-Gal4 driver ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The suppression observed by Kim, et al. is probably due to non-disjunction of the *PINK1* null flies. As predicted for a mechanism of VCP action that occurs through regulation of Mfn, VCP OE significantly reduced the accumulation of Mfn normally observed in both mutants ([Figure 3F](#fig3){ref-type="fig"}).10.7554/eLife.17834.008Figure 3.VCP overexpression suppresses mitochondrial defects in *PINK1* null, *parkin* null and *parkin mul1* double null mutants.(**A--E'**) Compared to wildtype (**A** and **A'**), *parkin* and *PINK1* mutants lose MitoGFP signal and accumulate large aggregates. VCP OE (IFM-Gal4\>UAS-VCP) significantly rescues the MitoGFP phenotype in both mutants. Filamentous actin is stained with Rhodamine Phalloidin (Red). (**A--E**) Lower magnification. Scale bar: 20 µm. (**A'--E'**) Higher magnification. Scale bar: 5 µm. (**A''--E''**) Toluidine Blue shows that vacuole formation in the muscle tissue in *parkin* and *PINK1* mutants is robustly suppressed by VCP OE. Thoraxes are assayed 2 days after eclosion. Scale bar: 30 µm. (**A'''--E'''**) At the ultrastructural level, wildtype (WT, IFM-Gal4 control) mitochondria are well aligned with compact cristae (**A'''**). *parkin* and *PINK1* mutants display swollen mitochondria with broken cristae (**B'''** and **D'''**). VCP OE (IFM-Gal4\>UAS-VCP) completely rescued the mitochondrial defects in both mutants (**C'''** and **E'''**). Thoraxes are sectioned at 2 days after eclosion. Scale bar: 1 µm. (**F**) VCP OE caused a decrease in Mfn accumulation in *parkin* and *PINK1* mutants. Mfn protein levels in the *parkin* mutant increased to 2.12 ± 0.69 as compared with wildtype (set as 1). VCP OE caused a decrease in Mfn levels in the *parkin* mutant to 1.26 ± 0.34 as compared with *parkin* (p=0.005, independent t test, N = 3. \*\*p\<0.01). In *PINK1* mutants, Mfn levels increased to 2.69 ± 0.11 as compared with wildtype, while VCP OE in *PINK1* mutant caused Mfn levels to decrease (1.77 ± 0.29 as compared with *PINK1*, p=0.023, independent t test, N = 3, \*p\<0.05). Normalized Mfn levels are shown as mean±½SD. (**G--I'**) Compared to wildtype, the *parkin mul1* mutant lacks the most MitoGFP signal and large aggregates are present (**G--H'**). VCP OE (IFM-Gal4\>UAS-VCP) rescues the MitoGFP phenotype in *parkin mul1* mutants (**I** and **I'**). Myofibrils are stained with Rhodamine Phalloidin (Red). (**G--I**) Lower Magnification, Scale bar: 20 µm; (**G'--I'**) Higher Magnification, Scale bar: 5 µm. (**J**) Expression pattern of EDTP-Gal4 and IFM-Gal4 in 3-day-old flies. EDTP-Gal4 driven UAS-MitoGFP signal is barely detected in the thorax, where the indirect flight muscle is located, suggesting that EDTP-Gal4 does not have sufficient flight muscle specific expression. MitoGFP is present at high levels in the thoraxes of IFM-Gal4 driven flies. Thorax structure is outlined with dashed white lines in white light and indicated with a white arrowhead in GFP field. (**K**) Schematic diagram showing that PINK/Parkin in parallel with Mul1 negatively regulates Mfn protein levels; VCP negatively regulates Mfn protein levels independent of these modifiers.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.008](10.7554/eLife.17834.008)10.7554/eLife.17834.009Figure 3---figure supplement 1.IFM-Gal4 driven UAS-VCP expression but not EDTP-Gal4 driven UAS-VCP rescues thorax defects in *PINK1* and *parkin* mutants in *Drosophila.*Thorax indentation (white arrows) is observed in both *PINK1* and *parkin* mutants, indicative of muscle tissue damage. EDTP-Gal4 driven UAS-VCP does not rescue this defect in *PINK1* and *parkin* mutants. IFM-Gal4 driven UAS-VCP completely rescues the thorax indentation in both mutants.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.009](10.7554/eLife.17834.009)

To further substantiate the finding that overexpression of *VCP* suppresses *parkin* null mutants, we also examined VCP's ability to suppress mitochondrial phenotypes associated with loss of both *parkin* and *mul1*. MUL1 (MULAN/MAPL) is a RING-containing E3 ligase that acts as a negative regulator of Mfn in both *Drosophila* and mammals ([@bib69]). When overexpressed, it suppresses *PINK1* and *parkin* null mutant phenotypes by degrading Mfn, while loss of *mul1* leads to increased levels of Mfn. Thus, *parkin mul1* double null mutants have strikingly more severe mitochondrial phenotypes than those observed in flies lacking *parkin* alone ([@bib69]). Remarkably, expression of VCP resulted in a dramatic rescue of mitochondrial morphology due to lack of both *parkin* and *mul1* ([Figure 3G--I'](#fig3){ref-type="fig"}). Together, these results suggest that VCP-dependent suppression of *PINK1* null, *parkin* null and *parkin mul1* double phenotypes occurs through downregulaton of Mfn levels ([Figure 3K](#fig3){ref-type="fig"}). Together, our observations argue that VCP regulates Mfn levels under non-stress conditions. They also show that VCP-dependent regulation of Mfn does not require PINK1 or Parkin. However, these results do not exclude the possibility that Parkin activation further promotes VCP-dependent Mfn degradation under some situations.

Expression of VCP disease mutants in muscle recapitulates pathological features of IBMPFD {#s2-4}
-----------------------------------------------------------------------------------------

To explore the basis of myopathy induced by VCP disease mutants we sought to create a model of IBMPFD in *Drosophila* muscle, as 90% of the IBMPFD patients show muscle phenotypes. Since *VCP* disease mutations are autosomal dominant, we characterized the consequences of disease mutant overexpression. The pathologies observed in IBMPFD patient muscle, and in muscle from VCP disease mutant transgenic and mouse knock-in models, include muscle cell death, changes in mitochondrial morphology, damaged tissue integrity, TAR DNA-binding protein 43 (TDP43) mislocalization to the cytosol, and formation of autophagic marker p62 and ubiquitin aggregates, signs of multisystem proteinopathy ([@bib25]; [@bib48]; [@bib38]; [@bib49]; [@bib39]; [@bib63]; [@bib2]). Previous studies of VCP disease mutants in *Drosophila* muscle showed effects on tissue integrity and mitochondria cristae structure ([@bib7]; [@bib27]), but not other pathologies. We thus investigated the pathologies due to mutant VCP expression. We focused on expression of VCP R152H and A229E (corresponding to Human VCP R155H and A232E, hereafter referred to as VCP RH and VCP AE), as they are the most frequent and the most severe mutations identified, respectively ([Figure 4A](#fig4){ref-type="fig"}). Anti-VCP antibody blotting shows that VCP WT, VCP RH and VCP AE are expressed at comparable level in the fly\'s thorax ([Figure 4B](#fig4){ref-type="fig"}). In wildtype flies, flies with IFM-Gal4 insertion, and flies with VCP WT expression, the muscle structure was healthy and intact 6 days after eclosion. No cell death was observed and mitochondria were densely packed and contained high levels of MitoGFP ([Figure 4C,D and D'](#fig4){ref-type="fig"}). Muscles also displayed a well-aligned myofibril structure ([Figure 4E and E'](#fig4){ref-type="fig"}). Together these observations indicate that increased expression of VCP is not overtly toxic. In contrast, muscle from flies expressing VCP RH or VCP AE under IFM-Gal4 control (thereafter called VCP RH or VCP AE flies) showed extensive cell death (97 ± 3.6% and 95.7 ± 5.1% muscle are TUNEL-positive), defective MitoGFP signals ([Figure 4D'' and D'''](#fig4){ref-type="fig"}), and severely disrupted muscle integrity ([Figure 4E'' and E'''](#fig4){ref-type="fig"}). In addition, while in wildtype and VCP WT flies TDP43 was found in IFM nuclear and sarcoplasmic compartments, IFMs from VCP RH and AE flies showed a decrease in the intensity of the nuclear signal, and an increase in the intensity of staining associated with puncta in the sarcoplasmic area ([Figure 4C,F--F'''](#fig4){ref-type="fig"}). Muscle from VCP RH and AE flies also contained large aggregates of anti-p62 and anti-ubiquitin staining. These were not observed in wildtype or VCP WT flies ([Figure 4G--H'''](#fig4){ref-type="fig"}). Importantly, the pathologies observed in flight muscle at day 6 post eclosion were not present at day 2 ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), suggesting the degenerative nature of the pathology, as with the human disease and mouse models ([@bib28]; [@bib13]; [@bib38]). Together, these observations indicate that IFM-specific expression of VCP RH and AE recapitulates a broad spectrum of IBMPFD disease pathologies and forms the strong basis for further investigation of disease mechanisms and treatment studies.10.7554/eLife.17834.010Figure 4.Expression of VCP disease mutants and *mfn* RNAi knocking down lead to pathology in adult muscle tissue.(**A**) Diagram of Human p97/VCP protein domains and two disease mutants, VCP R155H and A232E. Their corresponding *Drosophila* homologues are VCP R152H and A229E, hereafter referred to as VCP RH and AE. (**B**) Expression levels of UAS-VCP WT, RH and AE disease mutants expressed under IFM-Gal4 are comparable. (**C**) Diagram of *Drosophila* indirect flight muscle structure. Mitochondria (Green) and nuclei (Orange) are densely packed in between myofibrils (which contain large amounts of actin, Black). (**D--D\'\'\'**) MitoGFP (Green) and TUNEL staining (Red). 6-day-old WT (IFM-Gal4 control) flies and VCP WT flies have healthy muscles (no TUNEL staining) and are MitoGFP positive (**D** and **D\'**). 6-day-old VCP RH and AE expressing flies show high levels of TUNEL staining. 97 ± 3.6% and 95.7 ± 5.1% of RH (p=0.03. RH v.s. WT, independent t test) and AE (p=0.015, AE v.s. WT, independent t test) and are MitoGFP negative (**D\'\'** and **D\'\'\'**). Scale bar: 10 µm. (**E--E\'\'\'**) Toluidine Blue staining of muscle in WT, VCP WT, RH and AE flies. Myofibrils are well aligned with densely packed mitochondria in WT and VCP WT flies 6 days after eclosion (**E** and **E\'**). In VCP RH and AE flies fiber structure is disrupted, and mitochondria are misaligned and lightly stained, with empty spaces in between (**E\'\'** and **E\'\'\'**). Scale bar: 40 µm. (**F--F\'\'\'**) Anti-TDP43 antibody staining shows nuclear (white arrowhead) and sarcoplasmic localization of TDP-43 in WT and VCP WT adult fly muscle (**F** and **F\'**). In VCP RH and AE flies the nuclear signal disappears and the signal is increased in muscle sarcoplasm (**F\'\'** and **F\'\'\'**). Scale bar: 5 µm. (**G--G\'\'\'**) Anti-Ref(2)P/p62 antibody staining. The signal is weak and uniform in WT and VCP WT flies (**G** and **G\'**), and punctate in VCP RH and AE flies (**G\'\'** and **G\'\'\'**). Scale bar: 5 µm. (**H--H\'\'\'**) Anti-P4D1 ubiquitin antibody staining. Signal is weak and uniform in WT and VCP WT flies (**H\'** and **H\'**), and punctate in VCP RH and AE flies (**H\'\'** and **H\'\'\'**). Scale bar: 5 µm. (**I--M**) Effects of *mfn* RNAi in 8-day-old adult muscle tissue. (**I--M**) Wildtype muscle visualized with TUNEL and mitoGFP (**I**), anti-TDP43 (**J**), Toluidine blue (**K**), anti-p62 (**L**), and anti-ubiquitin (**M**). (**I\'--M\'**) *mfn* RNAi muscle visualized with the same probes as above. Scale bar: 30 µm in **K-K'**, 5 µm in the rest.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.010](10.7554/eLife.17834.010)10.7554/eLife.17834.011Figure 4---figure supplement 1.Muscle isolated from flies expressing VCP disease mutants does not show gross defects at 2 days post eclosion.(**A--D**) Toluidine Blue staining of overall muscle morphology shows that VCP RH and AE expression does not result in tissue damage. Scale bar: 40 µm. (**E--H**) Cell death, as visualized using TUNEL/MitoGFP assay, is absent (No Red Signal) and MitoGFP localization (Green) is normal in VCP RH and AE. Scale bar: 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.011](10.7554/eLife.17834.011)

VCP disease mutants are hyperactive with respect to downregulation of Mfn protein levels and inhibition of mitochondrial fusion {#s2-5}
-------------------------------------------------------------------------------------------------------------------------------

Next, we investigated the cellular basis of mitochondrial defects in our IBMPFD flies using electron microscopy. 6 days after eclosion, flies expressing VCP WT have smaller mitochondria as compared with control flies, but with intact cristae ([Figure 5A--B'](#fig5){ref-type="fig"}). In VCP RH and AE muscle, however, mitochondria are smaller in size, and more fragmented than in VCP WT flies. In addition, they also have severe ultrastructural defects under EM studies with a broken cristae ([Figure 5C--D'](#fig5){ref-type="fig"}). This phenotype is similar to that of flies with a muscle-specific Mfn knock down ([Figure 5E and E'](#fig5){ref-type="fig"}) ([@bib17]). Muscle from 2-day-old VCP RH and VCP AE flies also show similar phenotypes to Mfn knock down ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).10.7554/eLife.17834.012Figure 5.VCP disease mutants are hyperactive in downregulating Mfn protein levels and inhibiting mitochondrial fusion.(**A--B'**) Electronic microscopic images of muscle of different genotypes. Compared to WT (IFM-Gal4 control, **A** and **A'**), mitochondria are smaller with intact cristea in VCP WT (**B** and **B'**) 6 days after eclosion. Scale bar: 1 µm. (**C--E'**) Expression of VCP RH and AE leads to distorted fiber structure, and small mitochondria with broken or empty cristae. *mfn* RNAi flies have similar morphological defects in mitochondria (**E** and **E'**). Scale bar: 1 µm. (**F**) Expression of VCP RH and AE lead to a further reduction in Mfn as compared to VCP WT. Mfn levels in VCP WT are reduced to 0.73 ± 0.21 as compared with Gal4 control, which is set as 1 (p=0.037, independent t test, N = 3). Mfn levels in VCP RH and AE are reduced to 0.52 ± 0.14 (p=0.037, independent t test, N = 3) and 0.32 ± 0.16 (p=0.003, independent t test, N = 3) as compared with Gal4 control. Mfn levels are normalized with those of Hsp60, a mitochondria marker. Expression of VCP ATPase defective mutant E2Q (p=0.097, independent t test, N = 3) does not significantly change the Mfn level in fly thoraxes as compared with Gal4 control. n.s.: no statistical significance, p\>0.05. Normalized Mfn levels are shown as mean±½SD. (**G--L**) MitoGFP localization assay shows expression of VCP WT (**H**), RH (**I**) and AE (**J**) potently rescues the mitochondrial defects in *parkin* mutant (**G**). Expression of the ATPase defective mutant E2Q (**K**) or VCP RNAi (**L**) does not. Scale bar: 20 µm. (**M--R**) MitoGFP assay shows expression of VCP WT (**N**), RH (**O**) and AE (**P**) potently rescues the mitochondrial defects in *parkin mul1* double mutants (**M**). Expression of VCP E2Q (**Q**) and VCP RNAi (R) do not. Scale bar: 20 µm. (**S**) Western blot shows that increased Mfn levels normally present in a *parkin* null mutant are significantly decreased in VCP WT, RH and AE flies, but not in VCP E2Q flies. Mfn levels are further decreased in a *parkin* mutant expressing VCP RH (p=0.0228, independent t test, N = 3) or AE (p=0.00565, independent t test, N = 3), as compared to VCP WT. Samples are from 2-day-old fly thoraces. Normalized Mfn levels are shown as mean±½SD. \*p\<0.05; \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.012](10.7554/eLife.17834.012)10.7554/eLife.17834.013Figure 5---figure supplement 1.Expression of VCP disease mutants leads to small mitochondria with abnormal cristae, phenotypes similar to *mfn* RNAi knocking down.(**A--B'**) 2 days after eclosion, EM shows that compared to WT (IFM-Gal4 control, **A** and **A'**), VCP WT expression results in smaller mitochondrial with intact cristae (**B** and **B'**). (**C--E'**) VCP RH and AE also have smaller and fragmented mitochondria, but the cristae are abnormal (**C--D'**), similar to the phenotype of *mfn* RNAi flies (**E** and **E'**). Scale bar: 1 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.013](10.7554/eLife.17834.013)10.7554/eLife.17834.014Figure 5---figure supplement 2.Mfn expression can suppress mitochondrial defects observed in VCP RH and AE flies.(**A**) 2 copies of genomic rescue Mfn-HA (pCasper-Mfn-HA) lead to a heterogeneous mitochondrial phenotype in which some mitochondria are elongated. A' shows a typical elongated mitochondrion. (**B--E'**) In 2-day-old flies, expression of 2 copies pCasper-Mfn-HA (**C**, **C'** and **E**, **E'**) results in suppression of mitochondrial defects (fragmented mitochondria with abnormal cristae) in VCP RH (**B** and **B'**) and AE (**D** and **D'**) flies. Scale bar: 1 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.014](10.7554/eLife.17834.014)10.7554/eLife.17834.015Figure 5---figure supplement 3.Mfn expression does not significantly rescue the pathology in VCP RH and AE fly muscles.2 copies of the pCasper-Mfn-HA/eGFP transgene in VCP RH and AE flies at 6 days of age does not significantly alter muscle cell death assayed by TUNEL/MitoGFP (**A**, **A'** and **F**, **F'**, Scale bar: 10 µm), overall tissue disintegration (**B**, **B'** and **G**, **G'**, Scale bar: 40 µm), TDP43 mislocalization (**C**, **C'** and **H**, **H'** Scale bar: 5 µm), or the frequency of p62 (**D**, **D\'** and **I**, **I\'**, Scale bar: 5 µm) and ubiquitin positive aggregates (**E**, **E'** and **J-J'**, Scale bar: 5 µm).**DOI:** [http://dx.doi.org/10.7554/eLife.17834.015](10.7554/eLife.17834.015)

The strong mitochondrial phenotypes observed in VCP RH or VCP AE predicts that expression of VCP RH or VCP AE may result in a greater decrease in Mfn levels as compared with the expression of VCP WT. This is indeed what we observed ([Figure 5F](#fig5){ref-type="fig"}). This raises the possibility that VCP RH and AE are hyperactive alleles. To further substantiate these findings, we compared the Mfn levels in flies expressing VCP E2Q, a well-established ATPase defective mutant containing two mutations (fly or human residues by number E305Q and E578Q) that abolish the ATPase activity of the D1 and D2 domains. Expression of E2Q did not significantly change the Mfn levels ([Figure 5F](#fig5){ref-type="fig"}). As a control, the expression of any of the above forms of VCP did not alter expression levels of mitochondrial matrix protein Hsp60 ([Figure 5F](#fig5){ref-type="fig"}). These results suggest that VCP disease mutants are hyperactive with respect to promoting downregulation of Mfn levels.

Based on these observations, we hypothesized that VCP disease mutants should also rescue mitochondrial phenotypes in *parkin* and *parkin mul1* double mutants. As shown in [Figure 5G--J](#fig5){ref-type="fig"}, expression of VCP RH and AE mutants, but not VCP E2Q or VCP RNAi, robustly restored mitochondrial structure, as indicated by MitoGFP fluorescence, in the *parkin* null mutant ([Figure 5K and L](#fig5){ref-type="fig"}). Moreover, corresponding to the mitochondrial phenotypes, the accumulation of Mfn in *parkin* mutants was significantly reduced in the presence of VCP WT, RH and AE, with VCP RH and AE causing greater decreases in Mfn levels than VCP WT ([Figure 5S](#fig5){ref-type="fig"}). In addition, VCP RH and AE expression also robustly rescued the mitochondrial defects in the *parkin mul1* double null mutants, but an expression of VCP E2Q or VCP RNAi did not ([Figure 5M--R](#fig5){ref-type="fig"}). Taken together, these results indicate that VCP RH and AE disease mutants do not behave as ATPase defective or loss-of-function mutants, and instead are hyperactive with respect to regulation of Mfn.

Mfn downregulation is important to the muscle pathology in IBMPFD flies {#s2-6}
-----------------------------------------------------------------------

A prediction from our finding that Mfn downregulation is important for IBMPFD pathology is that downregulation of Mfn should result in phenotypes similar to those observed with an expression of VCP disease mutants. Indeed, *mfn* muscle-specific knockdown flies have fragmented mitochondria ([Figure 4I--I'](#fig4){ref-type="fig"}), TDP43 mislocalization ([Figure 4J--J'](#fig4){ref-type="fig"}), vacuole formation ([Figure 4K--K'](#fig4){ref-type="fig"}), p62 and ubiquitin accumulation ([Figure 4L--L' and M--M'](#fig4){ref-type="fig"}), as with the VCP disease mutants. Next we asked if *mfn* overexpression could rescue the phenotypes due to VCP RH and AE. Since *mfn* overexpression results in significant mitochondrial phenotypes, tissue disintegration and cell death on its own ([@bib69]), we are unable to address this question completely due to a technical limitation. We were, however, able to bring about a mild increase in Mfn levels through addition of 2 copies of an *mfn* genomic rescue transgene in the background of VCP RH and AE expressing flies. Interestingly, this resulted in a suppression of the mitochondrial fragmentation and cristae phenotypes in 2-day-old VCP RH and AE flies ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) but not the pathology observed in VCP RH and AE fly muscles at 6 days ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Together, our data suggest that downregulation of Mfn is an important contributor to IBMPFD muscle pathology.

IBMPFD patient fibroblasts with the VCP R155H mutation have mitochondrial respiratory chain and mitochondrial fusion defects {#s2-7}
----------------------------------------------------------------------------------------------------------------------------

Next, we extended our studies in IBMPFD patient fibroblasts. We focused our studies on *VCP^R155H/+^* cells (thereafter called RH cells), as fibroblasts harboring the *VCP^A232E/+^* mutation are not available. First, we characterized mitochondrial respiration in control and immortalized patient fibroblasts. As shown in [Figure 6A](#fig6){ref-type="fig"}, the basal level Oxygen Consumption Rate (OCR) in the VCP RH patient cells is slightly decreased compared to the healthy control, suggesting that baseline mitochondrial respiratory chain function is compromised in patient cells. Maximum OCR, measured in the presence of the uncoupler FCCP, is significantly decreased in VCP RH IBMPFD patient cells. The spare OCR, which is calculated by subtracting the basal OCR from the maximum OCR, provides a measure of reserve mitochondrial capacity for ATP generation. The spare OCR in IBMPFD patient cells is significantly decreased as compared with controls. Others have recently reported similar observations ([@bib37]).10.7554/eLife.17834.016Figure 6.IBMPFD patient cells carrying the *VCP^R155H/+^* mutation have decreased Mfn 1 and Mfn 2 levels and reduced mitochondrial fusion.(**A**) Oxygen consumption rates (OCR) in healthy control and IBMPFD patient fibroblasts. Inhibitory drugs were added at the time points indicated. Basal levels of OCR (p=0.026, independent t test, N = 8) and maximum (CCCP-stimulated) OCR (p=3.74E-06, independent t test, N = 8) are both decreased in the IBMPFD patient fibroblasts. The spare OCR is also significantly decreased (p=0.000024, independent t test, N = 8). (**B**) Mfn 1 and 2 levels are consistently decreased in three independent lysates from the IBMPFD patient fibroblasts when compared to the healthy control. Mfn 1 levels in patient fibroblasts are reduced to 0.66 ± 0.14 of the controls (p=0.001, independent t test, N = 5); Mfn 2 levels are reduced to 0.60 ± 0.14 of the controls (p=0.008, independent t test, N = 5). \*\*p\<0.01. Normalized Mfn 1 and 2 levels are shown as mean±½SD. (**C--D'**) Mitochondrial fusion assay utilizing photoactivatable mitoGFP (PA-GFP) in healthy control and IBMPFD patient fibroblasts. After laser photoactivation of a region (Red hollow square in C and D), cells were tracked for 30 min. (**E**) PA-GFP signal intensity (throughout the whole cell) is recorded every 3 minutes, and the rate of decrease of average GFP signal is a measure of mitochondrial fusion. Fusion rates are significantly decreased in the IBMPFD patient fibroblasts when compared to the healthy control (**C'**, **D'** and **E**, independent t test, \*p\<0.05).**DOI:** [http://dx.doi.org/10.7554/eLife.17834.016](10.7554/eLife.17834.016)

Disruption of mitochondrial fusion can result in defects in respiration similar to those observed in patient cells ([@bib10]). Mfn 1 and 2 levels in VCP RH cells were reduced to 0.66 ± 0.14 and 0.60 ± 0.14 respectively, as compared with age and gender matched healthy control cells (set as 1, [Figure 6B](#fig6){ref-type="fig"}). To explore the functional significance of this decrease, we carried out mitochondrial fusion assays using fibroblasts from healthy controls and patients. Both cell populations were transfected with a plasmid encoding a mitochondrial matrix targeted, photoactivated GFP (PA-GFP). Following photoactivation of GFP within a region of the cell, the GFP fluorescence signal spreads and the intensity decreases as these mitochondria fuse with non-activated neighboring mitochondria. Thus, in this assay an increased rate of fluorescence loss corresponds to increased mitochondrial fusion activity ([@bib36]). In control cells, PA-GFP gradually decreases after photoactivation; in the VCP RH IBMPFD patient cells, the GFP signal decrease is significantly delayed ([Figure 6C--D', E](#fig6){ref-type="fig"}). These data suggest that the VCP RH mutation results in a decrease in Mfn 1 and 2 levels that lead to impaired mitochondrial fusion. In addition, the VCP mutant impairs both basal and maximal mitochondrial respiratory function.

The VCP inhibitors NMS-873 and ML240 generate elongated mitochondria, block VCP disease mutant phenotypes, and VCP-dependent suppression of *PINK1* mutant mitochondrial defects {#s2-8}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

It has been controversial in the field whether VCP disease mutants with increased ATPase activity behave as dominant-active or dominant-negative mutants. Some studies show that VCP RH and AE, with enhanced ATPase activity ([@bib61]; [@bib70]; [@bib40]; [@bib33]; [@bib55]), result in hyperactivity in animal disease models ([@bib7]). However, other cell-based studies suggest they behave in a dominant negative fashion ([@bib49]; [@bib25]; [@bib27]; [@bib3]; [@bib30]). Understanding how VCP disease mutants behave is critical for understanding the disease process and finding possible therapies. We hypothesize that if an abnormally enhanced ATPase activity causes pathology, disease severity should ameliorate if ATPase activity is decreased through the use of VCP ATPase inhibitors. To test this hypothesis, we characterized the effects of VCP inhibitors *in vivo*.

Multiple VCP ATPase activity inhibitors have recently been described ([@bib8]). NMS-873, 3-\[3-Cyclopentylsulfanyl-5-(4\'-methanesulfonyl-2-methyl-biphenyl-4-yloxymethyl)-\[1, 2, 4\] triazol-4-yl\]-pyridine, an allosteric inhibitor of VCP ATPase activity, is a highly specific and robust VCP ATPase inhibitor ([@bib32]). ML240, 2-(2-Amino-1H-benzimidazol-1-yl)−8-methoxy-N-(phenylmethyl)−4-quinazolinamine is another potent inhibitor, which competitively blocks ATP binding to VCP ([@bib11]). These drugs and their derivatives were developed for treatment of cancers ([@bib32]; [@bib11]; [@bib18]; [@bib73]). The ability of these compounds to rescue defects in IBMPFD models has not been reported.

We first examined the effects of VCP inhibitors delivered to *Drosophila* through feeding. Various concentrations of drug or DMSO were included in food during the first to third larval instars, and muscle mitochondrial morphology was characterized at 2 and 6 days after eclosion. NMS-873 or ML240 feeding resulted in dramatic mitochondrial elongation in wildtype animals as visualized with MitoGFP using light microscopy ([Figure 7A--A''](#fig7){ref-type="fig"}) and at the ultrastructural level using EM ([Figure 7B--B'''](#fig7){ref-type="fig"}). These phenotypes are similar to those observed following VCP RNAi ([Figure 1C--C''](#fig1){ref-type="fig"}). In another respect, drug-treated animals developed normally (data not shown). The smaller mitochondria phenotype associated with overexpression of VCP WT was also significantly suppressed following feeding with 30 µM NMS-873 or 30 µM ML240 ([Figure 7C--C'''](#fig7){ref-type="fig"}). Feeding with NMS-873 and ML240 also reversed the phenotypic rescue of mitochondrial defects caused by expression of VCP WT, RH and AE in *PINK1* mutants ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Supporting these results, feeding with NMS-873 also resulted in a dose-dependent increase in the levels of Mfn ([Figure 7D](#fig7){ref-type="fig"}). Together, these observations suggest that NMS-873 and ML240 inhibit endogenous VCP *in vivo*, resulting in a phenocopy of loss of VCP function.10.7554/eLife.17834.017Figure 7.VCP inhibitors promote mitochondrial elongation.(**A--A''**) MitoGFP assay for mitochondrial morphology. Compared to DMSO-fed flies, 10 µM NMS-873 or ML240 feeding results in more fused mitochondria in 2-day-old flies. Scale bar: 5 µm. (**B--B''** and **C--C''**) In 6-day-old flies fed with 30 µM NMS-873 (**B'**) or 30 µM ML240 (**B''**), elongated mitochondria (outlined in dashed white lines) are observed in muscle. Mitochondria are small in VCP WT flies (**C**) as compared with WT (IFM-Gal4 control, **B**). This phenotype is reversed by 30 µM NMS-873 (**C'**) or 30 µM ML240 (**C''**) feeding and shifted towards a pro-fusion direction, as the mitochondria are also elongated as compared with WT (**B**). (**B'''** and **C'''**) Statistical analysis of mitochondrial size in EM cross sections. In wildtype flies, 30 µM NMS-873 or ML240 feeding results in a mitochondrial size increase to 6.46 ± 0.44 µm^2^ (p=0.007, independent t test, N = 45) or 5.75 ± 0.48 µm^2^ (p=0.032, independent t test, N = 39) as compared to the DMSO group (3.45 ± 0.27 µm^2^, N = 47). VCP WT expression results in small mitochondria (1.78 ± 0.05 µm^2^, N = 68) as compared with WT (**B**). Feeding of 30 µM NMS-873 (5.41 ± 0.40 µm^2^, p=0.000, independent t test, N = 44) or ML240 (4.90 ± 0.42 µm^2^, p=0.000, independent t test, N = 45) reverses these effects. Mitochondria size is shown as mean±½SEM. (**D**) pCasper-Mfn-eGFP levels accumulate in a dose dependent manner when treated with NMS-873 at 0.5 µM and 1 µM for 14 hr.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.017](10.7554/eLife.17834.017)10.7554/eLife.17834.018Figure 7---figure supplement 1.VCP inhibitor treatment blocks VCP WT and disease mutant rescue of mitochondrial defects in a *PINK1* mutant.(**A--B'**) MitoGFP assay shows that NMS-873 and ML240 feeding blocks the ability of VCP WT to rescue *PINK1* mutant mitochondrial phenotypes in a dose-dependent manner. 2.5 µM NMS-873 (**A**) and 10 µM ML240 (**B**) partially inhibit the rescue effect. The rescue effect is significantly blocked with 10 µM NMS-873 (**A'**) and 20 µM ML240 (**B'**). Scale bar: 20 µm. (**C--E''**) 10 µM NMS-873 blocks VCP WT (**C'**), RH (**D'**) and AE (**E'**) rescue of *PINK1* mutant mitochondrial phenotypes (**C--E**) as does feeding with 15 µM ML240 in rescue flies of VCP WT (**C''**), RH (**D''**) and AE (**E''**) in *PINK1* mutant. Scale bar: 5 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.018](10.7554/eLife.17834.018)

We then fed NMS-873 and ML240 to VCP RH and AE disease mutant flies and analyzed mitochondrial phenotypes, muscle viability and integrity in 6-day-old flies. Flies were fed with 30 µM NMS-873 or 30 µM ML240 from first instar larvae until 6 days after eclosion. In control and VCP WT expressing flies, NMS-873 and ML240 feeding resulted in normal development to adulthood (data not shown) and did not cause muscle death or tissue damage; all muscles were TUNEL negative and had an intact tissue structure ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Strikingly, NMS-873 and ML240 feeding largely prevented muscle cell death caused by expression of VCP RH or AE ([Figure 8A--B''](#fig8){ref-type="fig"}). It also significantly rescued disrupted muscle integrity ([Figure 8C--D''](#fig8){ref-type="fig"}). Rescue of mitochondrial size, cristae structure, and myofibril organization was also observed at the ultrastructural level ([Figure 8E--F''](#fig8){ref-type="fig"}). It is interesting to note that in the VCP disease mutants feeding groups ([Figure 8E', E'', F' and F''](#fig8){ref-type="fig"}), mitochondria remained somewhat smaller as compared to wildtype in [Figure 7B](#fig7){ref-type="fig"}. Elongated mitochondria, such as those observed in the wildtype and VCP WT feeding groups ([Figure 7B', B'', C' and C''](#fig7){ref-type="fig"}), were never observed in the VCP RH and VCP AE groups even though all were fed the same concentration of inhibitors. This partial suppression further suggests that these mutants are hyperactive. Finally, we note that VCP inhibitor feeding also resulted in significant rescue of a number of other phenotypes in VCP RH and AE expressing flies, including those associated with p62, ubiquitin and TDP43 ([Figure 8G--L''](#fig8){ref-type="fig"}). Together, these observations suggest that VCP disease mutants are hyperactive in multiple aspects, and that disease phenotypes can be suppressed by inhibition of VCP ATPase activity.10.7554/eLife.17834.019Figure 8.VCP inhibitors block mitochondrial defects, muscle tissue damage and muscle cell death in VCP disease mutant flies.(**A--B''**) Expression of VCP RH and AE leads to muscle cell death by 6 days after eclosion, as visualized through loss of MitoGFP and TUNEL positive signal in nuclei. In the DMSO feeding groups 3.4 ± 0.5% of VCP RH and 4.8 ± 0.6% of VCP AE flies are TUNEL negative. 30 µM NMS-873 or ML240 feeding since first instar larvae till 6 days after eclosion significantly blocks the muscle cell death, with 64.3 ± 17.0% (p=0.017) and 85.1 ± 19.0% (p=0.000) of VCP RH, and 80.9 ± 10.1% (p=0.002) and 95.6 ± 3.1% (p=0.000) of VCP AE muscles TUNEL negative. Data are shown as mean±½SD. Independent t test is used. Three independent rounds are performed, 15--20 flies are used each round. \*p\<0.05; \*\*p\<0.01. Scale bar: 10 µm. (**C--D''**) Toluidine Blue staining shows that 30 µM NMS-873 or ML240 feeding significantly rescue the disrupted muscle structure in VCP RH and AE flies. Scale bar: 40 µm. (**E--F''**) EM shows that 30 µM NMS-873 or ML240 feeding significantly rescue the broken myofibril structure and small mitochondria with broken cristae phenotypes in VCP RH and AE flies. Scale bar: 1 µm. Note that the mitochondria are still smaller than those from WT flies ([Figure 6B](#fig6){ref-type="fig"}). (**G--L''**) In 6-day-old flies, 30 µM NMS-873 (**G'**, **H'**, **J'** and **K'**) or ML240 (**G''**, **H''**, **J''** and **K''**) treatments result in a significant decrease in Ref(2)P/p62 (**G** and **J**) and ubiquitin (**H** and **K**) aggregates in VCP RH and AE expressing flies; TDP43 mislocalization (**I** and **L**) is partially rescued as the large sarcoplasmic signal decreases, but no nuclear signal is observed (**I'**, **I''**, **L'** and **L''**). Scale bar: 5 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.019](10.7554/eLife.17834.019)10.7554/eLife.17834.020Figure 8---figure supplement 1.VCP inhibitor feeding does not affect muscle viability and tissue integrity in 6-day-old flies.(**A--B''**) TUNEL/MitoGFP assay shows that feeding of 30 µM NMS-873 or ML240 does not cause muscle cell death in WT (IFM-Gal4 control, **A--A''**) and VCP WT flies (**B--B''**). Scale bar: 10 µm. (**C--D''**) Toluidine Blue assay shows that feeding of 30 µM NMS-873 or ML240 does not disrupt muscle integrity in WT (IFM-Gal4 control, **C--C''**) and VCP WT flies (**D--D''**). Scale bar: 40 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.020](10.7554/eLife.17834.020)

Low level of VCP inhibitor treatment suppresses mitochondrial fusion and respiration defects in IBMPFD patient's fibroblasts {#s2-9}
----------------------------------------------------------------------------------------------------------------------------

The above data demonstrated a decrease in Mfn 1 and 2 levels, mitochondrial fusion defects and impaired mitochondrial respiratory function in IBMPFD patient cells. Next, we explored the effects of these drugs on these changes in IBMPFD patient fibroblasts. In patient cells, a high concentration of ML240 (10 µM, with IC50 of 110 nM) or NMS-873 (10 µM, with IC50 of 30 nM) led to cell death, and NMS-873 directly inhibits mitochondrial respiration (data not shown). However, when lower concentrations of ML240 are used, robust rescue effects are observed ([Figure 9](#fig9){ref-type="fig"}). As shown in [Figure 9A](#fig9){ref-type="fig"}, immortalized IBMPFD patient fibroblasts have decreased Mfn 1 levels, and these are increased by treatment with 250 nM ML240 for 6 hr. Overall mitochondrial morphology of IBMPFD fibroblasts does not change in response to inhibitor treatment ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). However, in a more sensitive assay in which rates of fusion are measured directly, mitochondrial fusion defects in IBMPFD patient fibroblasts were significantly rescued after 6 hr of treatment with 250 nM ML240 ([Figure 9B](#fig9){ref-type="fig"}). Finally, 50 nM and 100 nM ML240 treatment for 4 days also significantly enhanced the basal and maximal oxygen consumption rate (OCR) in patient fibroblasts ([Figure 9C](#fig9){ref-type="fig"}). Similarly, 1 nM and 10 nM NMS-873 treatment for 6 days significantly enhanced the maximal oxygen consumption rate (OCR) in patient fibroblasts as well ([Figure 9D](#fig9){ref-type="fig"}). The fact that two inhibitors with different mechanisms generate similar results in terms of rescuing IBMFPD pathologies reduces the likelihood that these are off-targeting effects. Together, these data strongly support the effects of VCP inhibitors as potential therapeutic tools for IBMPFD disease.10.7554/eLife.17834.021Figure 9.VCP inhibitor treatment significantly suppresses mitochondrial respiratory chain and fusion defects in *VCP^R155H/+^* IBMPFD patient fibroblasts.(**A**) After treatment of 250 nM ML240 for 6 hr, Mfn 1 level of *VCP^R155H/+^* IBMPFD patient fibroblasts is elevated from 0.77 ± 0.02 to 1.05 ± 0.11 (p=0.037, independent t test, N = 3), as compared with healthy controls, for which values are set as 1. (**B**) After treatment with 250 nM ML240 for 6 hr, the mitochondria fusion assay shows that the decreased mitochondrial fusion observed in IBMPFD patient's fibroblasts is significantly reversed (independent t test, \*p\<0.05). (**C**) 50 nM and 100 nM ML240 treatment for 4 days significantly increases basal (p=0.0001, DMSO v.s. 50 nM ML240; p=0.0027, DMSO v.s. 100 nM ML240, Welch\'s unpaired t test, N = 8) and maximal oxygen consumption rate (p=0.0415, DMSO v.s. 50 nM ML240; p=0.0028, DMSO v.s. 100 nM ML240, Welch's unpaired t test, N = 8) in the IBMPFD patient fibroblasts harboring *VCP^R155H/+^* mutation. (**D**) 1 nM and 10 nM NMS-873 treatment for 6 days significantly increases maximal oxygen consumption rate (p=0.0021, DMSO v.s. 1 nM NMS-873; p=0.0395, DMSO v.s. 10 nM NMS-873, N = 8), but not basal oxygen consumption rate (p=0.0994, DMSO v.s. 1 nM NMS-873; p=0.1804, DMSO v.s. 10 nM NMS-873, N = 8). Welch's unpaired t test is used. \*p\<0.05, \*\*p\<0.01, n.s, no statistical significance.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.021](10.7554/eLife.17834.021)10.7554/eLife.17834.022Figure 9---figure supplement 1.ML240 and NMS-873 treatments do not significantly change the mitochondrial morphology in IBMPFD patients.In healthy control fibroblasts mitochondria display an elongated and interconnected phenotype (**A--A'**). IBMPFD patient's fibroblasts harboring *VCP^R155H/+^* mutation do not show a significant mitochondrial morphological difference (**B--B'**). Treatment of these cells with 100nM ML240 treatment for 4 days (**C-C'**) or 10 nM NMS-873 treatment for 6 days (**D--D'**) also does not result in a change in mitochondrial morphology (though see [Figure 9](#fig9){ref-type="fig"} for evidence that rates of fusion are altered). Scale bar: (**A--D**) 20 µm; Scale bar: (**A'--D'**): 5 µm. Anti-Tom20 antibody is used for mitochondial morphology assay.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.022](10.7554/eLife.17834.022)

Discussion {#s3}
==========

Missense mutations of VCP lead to the autosomal dominant disease IBMPFD. However, it is controversial whether these mutations cause disease through a dominant active or dominant negative manner. Moreover, the molecular mechanisms by which VCP mutations alter mitochondrial function are unclear. Here, we have investigated the endogenous function of VCP, cellular effects of expression of VCP disease mutants, and the ability of VCP inhibitors to suppress VCP disease pathology in *Drosophila* and patient fibroblasts. In summary, we have made the following findings:

Endogenous VCP regulates mitochondrial fusion ([Figure 10A](#fig10){ref-type="fig"}). Loss of VCP function leads to increased Mfn levels and increased mitochondrial size in multiple tissues. Conversely, VCP overexpression results in reduced Mfn levels and decreased mitochondrial size. VCP physically interacts with Mfn via domains that are also used to bind its substrates in other contexts. Thus, it is likely that Mfn is an endogenous VCP substrate. Here we provide the first *in vivo* evidence in muscle, the major disease tissue in IBMPFD, that Mfn is a specific endogenous target of VCP. Regulation of endogenous Mfn by VCP is unexpected, given that VCP is an abundant protein implicated in multiple cellular processes, but has not been shown to localize to mitochondria that are not depolarized by CCCP. We show that VCP-dependent removal of Mfn does not require Parkin or Mul1, E3 ligases known to ubiquitinate Mfn. How VCP brings about Parkin and Mul1-independent removal of Mfn requires further investigation.10.7554/eLife.17834.023Figure 10.Proposed mechanisms of VCP disease mutants mediated mitochondrial defects and potential therapeutic role of VCP inhibitors.(**A**) Under physiological conditions, VCP, independent of PINK1/parkin and Mul1, negatively regulates Mfn protein levels, which are critical for the proper balance of mitochondrial fusion and fission. (**B**) In the IBMPFD disease, the enhanced ATPase activity of a VCP disease mutant protein results in excessive loss of Mfn and mitochondrial fusion, leading to mitochondrial fusion defects. Besides the mitochondrial defects, VCP disease mutants also generate pathology including adult muscle tissue damage and muscle cell death. (**C**) VCP ATPase inhibitors robustly relieve the pathology caused by VCP disease mutants associated with hyperactive VCP activity while leaving normal VCP-dependent functions intact.**DOI:** [http://dx.doi.org/10.7554/eLife.17834.023](10.7554/eLife.17834.023)

IBMPFD is 100% penetrant, and myopathy is the most prevalent (affecting 90% of patients) and primary symptom of IBMPFD patients. We generated an IBMPFD disease model in adult *Drosophila* muscle, and used this system to monitor tissue pathology, and investigate the molecular mechanisms by which VCP disease mutants function. We show that compared to VCP WT, expression of VCP disease mutants results in tissue damage, mitochondrial fusion defects and decreased levels of Mfn ([Figure 10B](#fig10){ref-type="fig"}). These phenotypes are opposite to those associated with decreased levels of VCP, or expression of an ATPase defective mutant version of VCP. Expression of VCP disease mutants, but not a VCP ATPase defective mutant or VCP RNAi, also suppresses the mitochondrial defects mediated by accumulation of Mfn in *PINK1* null*, parkin* null, and *parkin mul1* double null mutants. Taken together, these results suggest that VCP disease mutants do not function as loss-of-function or dominant negative mutants, but rather as dominant activated mutants in regulating Mfn levels and bringing about mitochondrial fusion defects. This conclusion is further supported by our findings that mitochondrial fusion and Mfn levels are also decreased in VCP disease mutant fibroblasts.

Our finding that VCP overexpression suppresses a *parkin* null mutant in addition to a *PINK1* null stands in contrast to what was reported in Kim et al., who proposed that VCP-dependent degradation of Mfn required recruitment by Parkin. In addition, we also find that VCP overexpression suppresses phenotypes due to double mutants of *parkin* and *mul1*, which acts in a parallel pathway to degrade Mfn ([@bib69]). Together, these observations show that VCP-dependent regulation of Mfn does not require *PINK1* or *parkin*. The VCP-dependent degradation of Mfn we observe is also specific and unlikely to be mediated through a more general process such as mitophagy, as levels of several other mitochondrial proteins are not altered by VCP overexpression. However, these results do not exclude models in which Parkin activation further promotes VCP-dependent Mfn degradation, which may or may not involve mitophagy, under some conditions.

Regarding the mechanisms of VCP disease mutant action, *in vitro* biochemistry studies suggest that they have increased ATPase activities, thus favoring a dominant active model ([@bib61]; [@bib70]; [@bib40]; [@bib33]; [@bib55]). In addition, *in vivo* data from *Drosophila* shows that eye phenotypes caused by VCP disease mutant expression can be alleviated through loss of one copy of wildtype VCP. This also is consistent with models in which VCP mutants have increased activity ([@bib7]). In contrast, in cell culture studies Bartolome, et al showed that VCP disease mutant expression led to mitochondria respiratory chain defects, as did VCP RNAi ([@bib3]); Ritz, et al showed that VCP disease mutant expression impaired endocytosis to the same extent as that of VCP ATPase defective mutants ([@bib49]). While the above studies can be interpreted as showing that VCP disease mutants function as loss-of-function or dominant negative mutants, these results do not rule out the possibility that disease mutants are hyperactive alleles. For example, an alternative interpretation of the impairment of respiratory chain function observed following VCP disease mutant expression or following VCP RNAi is that either an increase or a decrease in the levels of VCP activity leads to mitochondrial defects, which is what we observed in this study.

Currently there is no treatment that can halt the progression of IBMPFD. Our findings that VCP disease mutants are hyperactive provide important therapeutic implications. Indeed, we find VCP inhibitors potently rescue multiple VCP disease phenotypes in flies and patient cells ([Figure 10C](#fig10){ref-type="fig"}). Importantly, suppression includes phenotypes beyond mitochondria ([Figure 10C](#fig10){ref-type="fig"}), involving TDP43, p62 and ubiquitin, suggesting that these inhibitors are likely to be effective in therapeutic settings. Of course, in order for VCP inhibitors to be useful as therapeutics, it will be necessary to inhibit mutant forms of VCP to an extent sufficient to suppress disease without bringing about a deleterious decrease in the activity of wildtype VCP. Our observation that *Drosophila* fed inhibitors are suppressed with respect to VCP disease phenotypes, but otherwise develop normally, suggests that this therapeutic goal may be possible. Finally, VCP disease mutants are associated with sporadic amyotrophic lateral sclerosis ([@bib1]), and hereditary spastic paraplegia ([@bib15]) and Charcot-Marie-Tooth disease ([@bib22]). Our findings suggest possible therapeutic values of VCP inhibitors for these diseases.

Materials and methods {#s4}
=====================

Molecular biology and constructs {#s4-1}
--------------------------------

Full length VCP (1-802aa), and truncated VCP cDNAs ∆N-VCP (186--802 aa), ∆N + D1-VCP (456--802 aa) and ∆D2-VCP (1--477 aa) were amplified from VCP cDNA derived from pUASt-VCP WT, a gift from Dr. Yun Nung Jan ([@bib51]). All cDNAs were subcloned into pUASt vectors as translational fusions fused with the 6 Myc tag using the Gateway cloning system (Invitrogen). To generate pUASt-Mfn-3Flag, Mfn cDNA was obtained from an EST clone (*Drosophila* Genome Research Center, RE04414), and subcloned into pUASt with the 3Flag tag. To generate VCP RNAi 2, microRNA precursors targeting the coding region of VCP transcripts were cloned into the pUASt vector. The MicroRNA-based silencing technology has been described previously ([@bib9]; [@bib21]). All constructs generated above were verified with sequencing.

*Drosophila* strains {#s4-2}
--------------------

UASt-VCP WT, VCP RH, AE and E2Q lines were gifts from Dr. Tzu Kang Sang ([@bib7]). IFM-Gal4, UAS-Mfn RNAi, pCasper-DRP1-HA, *PINK1^5^*, *parkin*^25^, *dpk*^21^, *parkin*^25^*mul*^A6^ were described previously ([@bib12]; [@bib17]; [@bib69]). VCP RNAi line1 flies were obtained from the Vienna *Drosophila* RNAi Center (VDRC 24354). VCP RNAi 2 was generated in the lab (see above). Efficiency of RNAi knocking down was verified by Western blot. 24B-Gal4, Mef2-Gal4 and EDTP-Gal4 were obtained from the Bloomington Stock Center at Indiana University. The pCasper-Mfn-HA flies ([@bib52]) were a kind gift from Dr. Hugo Bellen at Baylor College of Medicine, Texas. The pCasper-Mfn-eGFP construct was a kind gift from Dr. C.K. Yao at Academia Sinica, Taipei. Flies carrying pCasper-Mfn-eGFP and pUASt-VCP RNAi two constructs were created through injection in a *w^1118^* genetic background (pCasper-Mfn-eGFP, X chromosome; VCP RNAi line 2, second chromosome, Rainbow Transgenic Flies, Inc.). *vcp^K15502^*, hsFLP22, neoFRT42D, and Ubi-mRFP.NLS, neoFRT42D were obtained from Bloomington stock center. *Drosophila* strains were maintained in a 25°C humidified incubator or at room temperature.

Generation of germline nurse cell clones {#s4-3}
----------------------------------------

*vcp^K15502^* was recombined with neoFRT42D. Female flies with the genotype: hsFLP22 / +; *vcp^K15502^,* neoFRT42D / Ubi-mRFP.NLS, neoFRT42D or pCasper-Mfn-eGFP / hsFLP22; *vcp^K15502^,* neoFRT42D / Ubi-mRFP.NLS, neoFRT42D were heat-shocked at 37°C for 2 hr every day from second instar larvae until pupae formation. After eclosion, flies were fed with dry yeast paste for 24 hr to stimulate oogenesis. The egg chambers then were dissected and fixed in 3.7% formaldehyde/Schneider's Buffer for immunoflurescence assays.

TUNEL assay {#s4-4}
-----------

Fly thoraxes of the relevant genotypes were cut and fixed in 4% paraformaldehyde/Schneider's Buffer at desired time points. Indirect flight muscles were then dissected out and separated. Muscles were further blocked with blocking buffer \[50 mM Tris-Cl (pH 7.4), 0.1% Triton X-100, 188 mM NaCl\] and assayed using the In Situ Cell Death Detection Kit (Roche). 15--20 fly thoraxes are dissected for each round. For each experiment, at least three rounds were performed.

Toluidine blue staining and electronic microscopy {#s4-5}
-------------------------------------------------

Fly thoraxes of the relevant genotypes were fixed in 1% paraformaldehyde/1% glutaraldehyde/0.1 M Phosphate Buffer, post-fixed in 1% osmium tetroxide/ddH20, dehydrated in gradient ethanol and embedded in Epon 812. After polymerization, sections were obtained using either glass knives or diamond knife (Diatome). 1.0--1.5 µm sections were stained with Toluidine blue. 80--90 nm sections were stained with uranyl acetate and lead citrate and examined by transmission electron microscope (UCLA Brain Research Institute Electron Microscopy Facility). At least 3 thoraxes of each genotype were examined.

Mitochondrial cross-section size quantification {#s4-6}
-----------------------------------------------

Electron microscopy images (10,000X magnification) were analyzed in Image J Software (National Institute of Health). After setting the scale, each mitochondrion on the image was selected and its area calculated. An independent t test was used to test for statistical significance. At least three images were analyzed for each thorax and at least 3 thoraxes of each genotype were examined.

Immuofluoresence and confocal microscopy {#s4-7}
----------------------------------------

For assays in indirect flight muscles, muscles of the corresponding age and genotypes were fixed in 4% paraformaldehyde/Schneider's Buffer, permeabilized in 0.3% Triton-X100/PBS. Rhodamine Phalloidin (Invitrogen, 1:500) was used for myofibrile staining. Muscle pieces were incubated with anti-TDP43 rabbit monoclonal antibody (ProteinTech, 1:100), anti-Ref(2)P/p62 rabbit polyclonal antibody (Abcam, 1:100), anti-P4D1 monoclonal antibody (ENZO, 1:100) at 4°C overnight. Washes were followed by Goat anti-rabbit/mouse Alexa Fluor 546 secondary antibody (Invitrogen 1:200) at room temperature for 2 hr. For assays of egg chambers, egg chambers were fixed in 3.7% formaldehyde/Schneider's Buffer for 30 min and permeabilized with 0.4% Triton-X100/PBS for 4 hr. Egg chambers were incubated with anti-GFP rabbit polyclonal antibody (Invitorgen 1:100), anti-ATP5A mouse monoclonal antibody (Abcam, 1:100) at 4°C overnight and followed by goat anti-rabbit/mouse Alexa Fluor 488/546 secondary antibodies (Invitrogen 1:200) at 4°C overnight. Fibroblasts were fixed in 10% formalin for 10 min, 0.2% Triton-X100/PBS permeabilization for 15 min, 5% FBS/PBS blocking for 1 hr, anti-Tom20 mouse monoclonal antibody (BD, 1:200) at 4°C overnight and followed by goat anti-mouse Alexa Fluor 488 secondary antibodies (Invitrogen 1:200) at 4°C overnight. Images were taken using a LSM5 confocal microscope (Zeiss).

S2 cell culture, transfection and dsRNA treatment {#s4-8}
-------------------------------------------------

S2 cells were cultured in Schneider's Buffer, 10% FBS, 1% Penicillin and Streptomycin, 50 µM Tetracyclin at 25°C. Qiagen Effectene and was used as a transfection reagent according to the producer's instruction. Mfn DsRNA were designed according to a protocol from [www.flyrrnai.org](http://www.flyrrnai.org) and synthesized using the Mega T7 kit from Ambion. Cells were harvested 96 hr after dsRNA treatment. Mfn dsDNA-F: TGA GCA AAT ACC CCC AAA AG; Mfn dsDNA-R: GAT CTG GAG CGG TGA TTT GT.

Fibroblast cell culture {#s4-9}
-----------------------

Human primary fibroblasts from IBMPFD (GM21752) and age-matched control (GM00024) were obtained from the Coriell Institute for Medical Research (<https://catalog.coriell.org>) and grown in Dulbecco's Modified Eagle Medium (DMEM, Gibco) or Minimum Essential Media (MEM, Gibco) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and penicillin/streptomycin at 37°C and 5% CO2. Primary fibroblasts were immortalized by infection with retrovirus expressing hTERT (Addgene plasmid \#1771). Infected cells were selected in puromycin (1.5 ug/mL) for 1 week and maintained in 1 ug/ml puromycin.

Protein lysates and western blot {#s4-10}
--------------------------------

S2 cells, fly thoraxes or fibroblasts were lysed in RIPA Buffer with Protease Inhibitors (Roche) and 200 mM PMSF (Sigma). Protein lysates were centrifuged at 16,000g for 15 mins, and the supernatants boiled with 6XSDS sample Buffer (Bioland) at 95°C for 5 mins. Proteins were separated in SDS-PAGE Gels. Gels were transferred to PVDF membrane (Millipore) and incubated with primary antibody at 4°C overnight. Following several washes, blots were then incubated with secondary antibodies for 2 hr at room temperature and then washed extensively. Primary antibodies used include: Anti-HA mouse monoclonal antibody (Millipore, 1:1000), Anti-Myc mouse monoclonal antibody (Millipore,1:3000), Anti-Flag rabbit polyclonal antibody (Genscript, 1:2000), Anti-GFP rabbit polyclonal antibody (Invitrogen, 1:3000), Anti-Actin rabbit polyclonal antibody (Sigma, 1:2000), Anti-Tubulin mouse monoclonal antibody (Sigma, 1:4000), Anti-Porin mouse monoclonal antibody (Abcam, 1:2000), Anti-VCP rabbit monoclonal antibody (Cell Signalling Technology, 1:2000), Anti-Human Mfn 1 and 2 mouse monoclonal antibody (Abcam, 1:2000), Anti-MnSOD rabbit polyclonal antibody (Abcam, 1:2000) and Anti-NDUSF3 mouse monoclonal antibody (Abcam, 1:2000). Anti-*Drosophila* Mfn Rabbit polyclonal antibody (1:3000) was a gift from Dr. Alexander Whitworth ([@bib74]). Donkey anti-mouse and anti-rabbit HRP conjugated secondary antibodies (GE Healthcare, 1:10000 or 20000) were used.

Co-immunoprecipitation {#s4-11}
----------------------

48 hr after transfection, S2 cells were harvested and lysed in the RIPA Buffer with protease inhibitors. Protein lysates were incubated with Dynabeads G and primary antibody (Anti-Myc mouse monoclonal antibody, Millipore 1:300) at 4°C overnight and washed in 0.1%Tween/PBS four times and eluted in 2XSDS sample buffer (BioRad) and denatured at 95°C. The samples are assayed by western blot.

*In vivo* and *in vitro* VCP inhibitors treatment {#s4-12}
-------------------------------------------------

Powdered forms of NMS-873 (Selleckchem) and ML240 (Sigma-Aldrich) were dissolved in DMSO as stocks. Stock solution and DMSO as the vehicle control were diluted in ethanol/ddH2O and mixed with *Drosophila* food. Food dye was added to ensure thorough mix. Parents of desired genotypes were put in DMSO or inhibitors containing food for 3 days and removed. Thus, all growth following egg laying occurred in the presence of inhibitors. Immediately after eclosion, the progeny were transferred to newly prepared food vials containing the same concentration of DMSO or inhibitors. The progeny was assayed at the time points stated in the text. For human fibroblast treatment, stock solution of ML240, NMS-873 and DMSO vehicle control were diluted to the desired concentration and added to the culture media. Media were changed each day if the treatment was longer than 24 hr.

Mitochondrial fusion assay in fibroblasts {#s4-13}
-----------------------------------------

The mitochondrial fusion assay was performed using photoactivatable mitoGFP (PA-GFP) localized to the mitochondrial matrix as previously described ([@bib36]; [@bib26]). Briefly, immortalized fibroblasts were infected with retroviruses expressing matrix-treated DsRed and matrix-targeted PA-GFP to create stable cell lines. Cells were plated on glass coverslips (LabTek) and imaged live at 37°C on an LSM 710 confocal microscope (Carl Zeiss, Inc.). PA-GFP is activated in a region of interest (5 µm x 5 µm) by illumination with a 405 nm laser. The activated signal is collected in z-stacks every 3 min over the next 30 min. Fusion events result in the dilution of the activated signal, and the average pixel intensity (for the entire cell) over time is a measurement of fusion rates ([@bib26]). P-values are calculated using a Student's t-test on the slopes of intensity versus time for individual measurements (\>20 per genotype).

Mitochondrial respiration measurements {#s4-14}
--------------------------------------

Oxygen consumption rates (OCR) were measured in immortalized fibroblasts using a Seahorse Biosciences Extracellular Flux Analyzer (Model XF96). Briefly, 10,0000 cells/well were plated the day before measurement into a 96 well culture plate. On the day of measurement, the media was exchanged for non-bicarbonate-containing DMEM (Sigma-Aldrich Cat. \#D5030) media using the Seahorse PrepStation, and allowed to equilibrate for 1 hr at 37°C in room air prior to initiating measurements. Oxygen levels were measured over 5 min periods. Oxygen consumption rate was measured under basal and stress conditions as indicated. Oligomycin inhibits complex V and blocks ATP production dependent on respiration. CCCP uncouples oxidative phosphorylation and ATP production. It maximizes respiration without ATP synthesis. Antimycin A inhibits Complex III and thus blocks proton pumping and membrane potential formation. Drugs were injected automatically as indicated in the figure legends (Oligomycin 5 µM, CCCP 10 µM, Antimycin A 1 µM). For drug pre-treatment studies ([Figure 9C--D](#fig9){ref-type="fig"}), 5000 cells/well were plated into 96 well culture plates and pre-treated with ML240 for 4 days and NMS-873 for 6 days prior to OCR measurement. OCR values were normalized from total cellular content via sulforhodamine B measurements.

Statistical analysis {#s4-15}
--------------------

The overall study design was a series of controlled laboratory experiments in *Drosophila* and human fibroblasts, as described in detail in the Figure legends sections. In all experiments, animals were randomly assigned to various experimental groups. The experiments were replicated at least three times (N was noted in each experiment) and the final analysis was presented. For in vivo experiments, 10--20 flies per group were used for each experiment. For the human fibroblasts experiments, details are described in the above methods sections. The data were analyzed using Statistical Package for the Social Sciences (SPSS) 16.0. The P values were assessed using a two-tailed unpaired Student's t test with P values considered significant as follows: \*p\<0.05 and \*\*p\<0.01. For seahorse assay in human fibroblasts, Welch's unpaired t test was used.
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Thank you for submitting your article \"VCP inhibitors relieve Mitofusin-dependent mitochondrial defects due to VCP disease mutants\" for consideration by *eLife*. Your article has been favorably evaluated by K VijayRaghavan (Senior Editor and Reviewer \#3) and three reviewers, one of whom, Hugo Bellen, is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In the current manuscript, Zhang et al. explore the role of VCP in mitochondrial dynamics as well as the associated pathogenesis in IBMPFD (inclusion body myopathy, Paget\'s disease of the bone with frontotemporal dementia). VCP is a type II ATPase that has predicted functions in many processes such as mitochondrial function, cell cycle regulation, DNA repair, ERAD, endolysosomal sorting, autophagy, and organelle biogenesis. This manuscript shows that overexpression of VCP in *Drosophila* indirect flight muscles resulted in smaller mitochondria whereas VCP RNAi caused mitochondria to elongate. Similarly, mitochondria in nurse cells with loss of function VCP alleles are more elongated or clumped. Muscle lysates with higher VCP levels displayed less Mfn expression and Nurse cells with loss of function VCP alleles showed increased Mfn levels. All these results are consistent with prior reports in mammals and flies that VCP mediates degradation of mitofusins. The authors do correct an apparent error in the literature by showing VCP OE rescues muscle phenotypes caused by both PINK1 and Parkin loss. In general, the paper is well written, the figures are nice, and the data are compelling. However, some data sets are not novel, and the reader has a hard time distinguishing what is novel and what is not. In addition, a number of important issues remain to be addressed.

1\) Overexpression of VCP mutants (RH and AE) caused p62 aggregates and ubiquitin inclusions and mitochondrial defects. Correlating with one aspect of VCP mutant expression, Mfn mutation caused similar mitochondrial defects. Do Mfn mutant flies display p62 aggregates and ubiquitin inclusions too?

2\) In [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"} the authors show that mild Mfn overexpression suppresses the mitochondrial fragmentation caused by VCP RH and AE expression. Does Mfn overexpression rescue the TUNEL, Toluidine Blue, TDP43, p62 and ubiquitin phenotypes shown in [Figure 4](#fig4){ref-type="fig"} to be caused by VCP RH and AE expression? One main unresolved mystery is whether or not the VCP mutation-induced defects that are rescued by VCP inhibition ([Figure 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}) arise from the Mfn decrease and subsequent mitochondrial defects or from effects on other VCP involved pathways.

3\) Is the conclusion that the small effects on Mfn levels seen in patient cells in [Figure 6](#fig6){ref-type="fig"} causes or contributes to IBMPFD pathophysiology?

4\) Do Mfn haploinsufficient mice or flies (or people) display phenotypes?

5\) Does increasing Mfn levels in IBMPFD cells rescue the respiratory defects noted in [Figure 6A](#fig6){ref-type="fig"}?

6\) Do the VCP inhibitors cause mitochondria to elongate in the IBMPFD patient cells?

7\) A second main undetermined issue is whether or not the VCP inhibitors cause their phenotypic rescue effects by inhibiting VCP or through other off target activities. A mutant VCP that is functional but insensitive to the inhibitors would be a rigorous way to explore that important issue.
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Author response

*Summary:*

*In the current manuscript, Zhang et al. explore the role of VCP in mitochondrial dynamics as well as the associated pathogenesis in IBMPFD (inclusion body myopathy, Paget\'s disease of the bone with frontotemporal dementia). VCP is a type II ATPase that has predicted functions in many processes such as mitochondrial function, cell cycle regulation, DNA repair, ERAD, endolysosomal sorting, autophagy, and organelle biogenesis. This manuscript shows that overexpression of VCP in Drosophila indirect flight muscles resulted in smaller mitochondria whereas VCP RNAi caused mitochondria to elongate. Similarly, mitochondria in Nurse cells with loss of function VCP alleles are more elongated or clumped. Muscle lysates with higher VCP levels displayed less Mfn expression and Nurse cells with loss of function VCP alleles showed increased Mfn levels. All these results are consistent with prior reports in mammals and flies that VCP mediates degradation of mitofusins. The authors do correct an apparent error in the literature by showing VCP OE rescues muscle phenotypes caused by both PINK1 and Parkin loss. In general, the paper is well written, the figures are nice, and the data are compelling. However, some data sets are not novel, and the reader has a hard time distinguishing what is novel and what is not. In addition, a number of important issues remain to be addressed.*

We thank the reviewers for suggesting that we distinguish what is novel and what is not. Here are the novel findings of the paper:

1\) While some groups have reported the effects of VCP overexpression on Mfn levels, we report here that loss of endogenous VCP in *Drosophila* nurse cells leads to an increase in the levels of endogenous Mfn. This is important as VCP is a highly abundant protein with many targets. To demonstrate that endogenous VCP regulates Mfn in vivo is highly significant.

2\) We have shown that overexpression of VCP suppresses parkin null mutant phenotypes in addition to PINK1 null mutants. This alters the interpretation of how VCP overexpression functions to regulate PINK1/parkin related pathway.

3\) No prior report suggests that VCP disease mutants suppress Mfn in a dominant active fashion.

4\) No prior report suggests that human disease fibroblasts exhibit mitochondrial fusion defects that are dependent on Mfn.

5\) No prior report suggests that VCP inhibitors reverse the pathology related to disease models or human disease fibroblasts.

We are grateful that the reviewers made this suggestion and have incorporated these points in the manuscript.

*1) Overexpression of VCP mutants (RH and AE) caused p62 aggregates and ubiquitin inclusions and mitochondrial defects. Correlating with one aspect of VCP mutant expression, Mfn mutation caused similar mitochondrial defects. Do Mfn mutant flies display p62 aggregates and ubiquitin inclusions too?*

This is a very interesting question and we thank reviewers for suggesting this. We performed the experiments and the results are now incorporated in [Figure 4](#fig4){ref-type="fig"}. As mfn loss-of-function mutants are homozygous lethal, we examined phenotypes due to muscle-specific mfn knockdown. These flies show TDP mislocalization ([Figure 4J, J](#fig4){ref-type="fig"}'), tissue disintegration ([Figure 4K, K](#fig4){ref-type="fig"}'), p62 and ubiquitin accumulation ([Figure 4L, L' and M', M'](#fig4){ref-type="fig"}), as with the VCP IBMPFD mutants.

*2) In [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"} the authors show that mild Mfn overexpression suppresses the mitochondrial fragmentation caused by VCP RH and AE expression. Does Mfn overexpression rescue the TUNEL, Toluidine Blue, TDP43, p62 and ubiquitin phenotypes shown in [Figure 4](#fig4){ref-type="fig"} to be caused by VCP RH and AE expression? One main unresolved mystery is whether or not the VCP mutation-induced defects that are rescued by VCP inhibition ([Figure 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}) arise from the Mfn decrease and subsequent mitochondrial defects or from effects on other VCP involved pathways.*

This is an interesting question, and we performed the experiments and added new figure panels in the Supplementary figure. We have shown that mild (2-fold) increases of Mfn levels using the genomic rescue flies, while rescuing mitochondrial fragmentation cause by VCP disease mutant RH and AE expression at day 2 ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}, does not rescue muscle tissue integrity, muscle cell death, TDP43 mislocalization, p62 and ubiquitin aggregates seen at day 6 ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). However, it is important to note that we are unable to fully address whether overexpression of mfn can suppress phenotypes due to VCP RH and AE expression, since mfn overexpression by itself shows strong phenotypes -- TUNEL positivity and tissue disintegration assays by Toluidine Blue (Yun et al., 2014).

Together, our observations suggest that VCP regulates endogenous levels of Mfn, and that a 2-fold increase of Mfn levels can suppress mitochondrial abnormalities. While we cannot ascertain, for technical reason, whether VCP inhibition rescues VCP IBMPFD pathology solely due to a decrease in Mfn, these results argue that downregulation of Mfn is at least an important contributor to IBMPFD muscle pathology.

*3) Is the conclusion that the small effects on Mfn levels seen in patient cells in [Figure 6](#fig6){ref-type="fig"} causes or contributes to IBMPFD pathophysiology?*

We speculate that the Mfn level decrease and mitochondrial fusion defects probably contribute to IBMPFD pathology as one of multiple pathogenesis pathways, given that VCP is involved in multiple other pathways. As stated immediately above, we cannot fully address this.

*4) Do Mfn haploinsufficient mice or flies (or people) display phenotypes?*

In *Drosophila*, homozygous Mfn loss-of-function flies (*mfn^B^*) are 3^rd^ instar laval lethal \[Sandovol, et al., *eLife*, 2014,PMID: 25313867\]. *mfn^B^/+* heterozygous flies do not display muscle tissue damage or mitochondrial morphology defects as compared to wildtype (data not shown). In mice, skeletal muscle from *mfn1* and *mfn2* tissue-specific double knockout mice display decreased muscle volume, and mitochondrial fragmentation with abnormal cristae. But *mfn1-/- mfn2+/-* and *mfn1+/- mfn2-/-* mice grow to normal size and skeletal muscle mitochondria have mild structural changes \[Chen, et al., Cell, 2010, PMID: 20403324\]. In humans, no case on Mfn haploinsufficiency has been reported.

*5) Does increasing Mfn levels in IBMPFD cells rescue the respiratory defects noted in [Figure 6A](#fig6){ref-type="fig"}?*

This is a very interesting question. However, we are unable to address it unambiguously. This is because Mfn1 or 2 overexpression results in toxic effects on human cells. As reported extensively in the literature (see below), Mfn1 or 2 overexpression results in perinuclear clustering of fragmented mitochondria, \[Santel et al; Huang et al\]. Functionally, Mfn1 overexpression leads to decreased mitochondrial ATP generation, membrane potential and decreased mitochondrial motility \[Park et al., 2008; Park et al., 2012\]; Mfn2 overexpression leads to significant loss of mitochondrial membrane potential and cell apoptosis \[Huang et al\]. Mfn1 overexpression increases cell's vulnerability under stress conditions \[Park et al., 2014\]. We now note in the text that this question remains outstanding.

1 Santel, A., et al., Mitofusin-1 protein is a generally expressed mediator of mitochondrial fusion in mammalian cells.Journal of cell science, 2003. 116(Pt 13): p. 2763-74.

2 Huang, P., T. Yu, and Y. Yoon, Mitochondrial clustering induced by overexpression of the mitochondrial fusion protein Mfn2 causes mitochondrial dysfunction and cell death. European journal of cell biology, 2007. 86(6): p. 289-302.

3 Park, K.S., et al., Selective actions of mitochondrial fission/fusion genes on metabolism-secretion coupling in insulin-releasing cells.The Journal of biological chemistry, 2008. 283(48): p. 33347-56.

4 Park, K.S., A. Wiederkehr, and C.B. Wollheim, Defective mitochondrial function and motility due to mitofusin 1 overexpression in insulin secreting cells. The Korean journal of physiology & pharmacology: official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2012. 16(1): p. 71-7.

5 Park, Y.Y., et al., MARCH5-mediated quality control on acetylated Mfn1 facilitates mitochondrial homeostasis and cell survival. Cell death & disease, 2014. 5: p. e1172.

*6) Do the VCP inhibitors cause mitochondria to elongate in the IBMPFD patient cells?*

To address reviewer's comments, we performed the mitochondrial morphological assay and include the new [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}. We do not see mitochondrial morphological changes. However, in a more sensitive assay, which measures the rate of mitochondria fusion directly, the decreased frequency of fusion observed in IBMPFD patient cells is significantly suppressed in the presence of a VCP inhibitor. This was our original [Figure 9](#fig9){ref-type="fig"}. We now note more explicitly in the text these points.

*7) A second main undetermined issue is whether or not the VCP inhibitors cause their phenotypic rescue effects by inhibiting VCP or through other off target activities. A mutant VCP that is functional but insensitive to the inhibitors would be a rigorous way to explore that important issue.*

This point could be tested if there were VCP mutants that did not affect ATPase activity while still being resistant to NMS-873 and ML240. Unfortunately, no such mutants have been reported to date. Importantly, the experiments we report here are carried out with two VCP inhibitors that function through distinct mechanisms. NMS-873 inhibits VCP function through allosteric change of the protein structure \[Magnaghi et al., Nat Chem Biol, 2013, PMID: 23892893\], while ML240 function through competitive inhibition of ATP binding \[Chou et al., ChemMedChem, 2013, PMID: 23316025\]. The fact that two inhibitors with different mechanisms generate similar results in terms of rescuing IBMFPD pathologies suggests these are unlikely to be off-targeting effects.

[^1]: Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, United States.
